Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events -

Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events
Information type: Other primary research
Source: Diabetes Care
Specialities: Cardiovascular system disorders | Diabetes
Summary
UK cohort study of 17,604 patients with type 2 diabetes initiating sulfonylurea monotherapy found after mean follow up of 1.2 years, nonspecific, long-acting sulfonylureas did not have an increased risk of cardiovascular adverse events vs specific, short-acting sulfonylureas.
UKMi comment

These data are limited by their observational nature and only relate to first-line use of sulphonylureas.

Compared with specific, short-acting sulfonylureas (n=15,741; gliclazide, glipizide, and tolbutamide), nonspecific, long-acting sulfonylureas (n=1,863; glyburide and glimepiride) were not associated with an increased risk of acute myocardial infarction (HR 0.86; 95% CI 0.55–1.34), ischemic stroke (0.92; 0.59–1.45), cardiovascular death (1.01; 0.72–1.40), or all-cause mortality (0.81; 0.66–1.003). However, nonspecific, long-acting sulfonylureas (glyburide and glimepiride) were associated with an increased risk of severe hypoglycaemia (2.83; 1.64–4.88).
Related links: